The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

New European guidelines redefine Metabolic dysfunction-associated steatotic liver disease (MASLD) care, offering clearer ...

Often symptomless, fatty liver disease is becoming a leading cause of liver cancer. Learn the role of daily habits, early ...

South Korea: A large population-based study from South Korea has revealed a significant association between cholecystectomy ...

A new analysis from the Chile BiLS study evaluated the reliability of ultrasound imaging for diagnosing SLD in a high-risk ...

One of the challenges with liver disease is that it can be a silent threat. In its early stages, it may cause only vague ...

Steatotic liver disease (SLD) was highly prevalent among adults with cardiometabolic risk factors, prolonged alcohol intake, or both combined and affected 70% of participants overall.

China: A large-scale U.S. analysis has revealed that people living with both type 2 diabetes (T2DM) and chronic kidney ...

Medically reviewed by Robert Burakoff, MD Fatty liver disease is a health condition in which fat builds up in the liver. This ...

Fatty liver disease, now termed MASLD, often presents subtle abdominal symptoms like bloating and discomfort, even before ...

Source Reference: Ochoa-Allemant P, et al "Adverse liver outcomes, cardiovascular events, and mortality in steatotic liver disease" JAMA Intern Med 2025; DOI: 10.1001/jamainternmed.2025.1809.